ADX-2191 (intravitreal methotrexate 0.8%)
ADX-2191-PVR-001
Phase 3 small_molecule completed
Quick answer
ADX-2191 (intravitreal methotrexate 0.8%) for Proliferative Vitreoretinopathy is a Phase 3 program (small_molecule) at Aldeyra Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aldeyra Therapeutics
- Indication
- Proliferative Vitreoretinopathy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed